MX2021002992A - Composiciones de toxina clostridial y acido hialuronico. - Google Patents

Composiciones de toxina clostridial y acido hialuronico.

Info

Publication number
MX2021002992A
MX2021002992A MX2021002992A MX2021002992A MX2021002992A MX 2021002992 A MX2021002992 A MX 2021002992A MX 2021002992 A MX2021002992 A MX 2021002992A MX 2021002992 A MX2021002992 A MX 2021002992A MX 2021002992 A MX2021002992 A MX 2021002992A
Authority
MX
Mexico
Prior art keywords
compositions
hyaluronic acid
clostridial toxin
acid compositions
antioxidant
Prior art date
Application number
MX2021002992A
Other languages
English (en)
Inventor
Ron Broide
Cindy Wu
James Cunningham
Marianne Do
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2021002992A publication Critical patent/MX2021002992A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen composiciones farmacéuticas que prolongan el efecto y duración de un ingrediente activo de toxina clostridial. Las composiciones pueden ser composiciones líquidas o sólidas y comprenden un ácido hialurónico no reticulado o sal de este tal como se describe en la solicitud, un tensioactivo y un antioxidante. En algunas modalidades, las composiciones comprenden un tensioactivo seleccionado de un poloxámero y un polisorbato; un antioxidante seleccionado de metionina, N-acetil cisteína, ácido etilendiaminotetraacético y combinaciones de estos, y, opcionalmente, un agente de tonicidad y/o un lioprotector seleccionado de, por ejemplo, trehalosa, sucrosa.
MX2021002992A 2018-09-13 2019-09-13 Composiciones de toxina clostridial y acido hialuronico. MX2021002992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731063P 2018-09-13 2018-09-13
PCT/US2019/051173 WO2020056371A1 (en) 2018-09-13 2019-09-13 Clostridial toxin-hyaluronic acid compositions

Publications (1)

Publication Number Publication Date
MX2021002992A true MX2021002992A (es) 2021-11-12

Family

ID=68069925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002992A MX2021002992A (es) 2018-09-13 2019-09-13 Composiciones de toxina clostridial y acido hialuronico.

Country Status (10)

Country Link
US (2) US20200108129A1 (es)
EP (1) EP3849512A1 (es)
JP (1) JP2022500426A (es)
KR (1) KR20210057129A (es)
CN (1) CN112888454A (es)
AU (1) AU2019339519A1 (es)
BR (1) BR112021004771A2 (es)
CA (1) CA3112394A1 (es)
MX (1) MX2021002992A (es)
WO (1) WO2020056371A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
KR20240023684A (ko) 2016-09-13 2024-02-22 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
WO2024126649A1 (en) 2022-12-15 2024-06-20 Merz Pharma Gmbh & Co. Kgaa Injectable gel comprising botulinum toxin and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5099013A (en) 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US7758872B1 (en) 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
WO2006096164A1 (en) 2005-03-03 2006-09-14 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2016204034B2 (en) * 2005-10-06 2017-12-21 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
CN105833254A (zh) * 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
SG174350A1 (en) 2009-03-13 2011-10-28 Allergan Inc Cells useful for immuno-based botulinum toxin serotype a activity assays
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
SG11201805195YA (en) * 2016-03-02 2018-07-30 Merz Pharma Gmbh & Co Kgaa Composition comprising botulinum toxin
KR20240023684A (ko) * 2016-09-13 2024-02-22 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물

Also Published As

Publication number Publication date
KR20210057129A (ko) 2021-05-20
WO2020056371A1 (en) 2020-03-19
JP2022500426A (ja) 2022-01-04
CN112888454A (zh) 2021-06-01
US20200108129A1 (en) 2020-04-09
EP3849512A1 (en) 2021-07-21
BR112021004771A2 (pt) 2021-11-09
CA3112394A1 (en) 2020-03-19
US20230158129A1 (en) 2023-05-25
AU2019339519A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
SA519401298B1 (ar) تركيبات مثبِتة للسم المطثي غير البروتيني
MX2021002992A (es) Composiciones de toxina clostridial y acido hialuronico.
EP3855910A4 (en) Synergistic pesticidal compositions and methods for delivery of active ingredients
EP3672409A4 (en) SYNERGISTIC PESTICIDE COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE SUBSTANCES
BR112017008660A2 (pt) formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
MX2020009010A (es) Formulaciones inyectables de larga duracion que comprenden un agente activo de isoxazolina, metodos y usos de las mismas.
ECSP20081995A (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
CL2020002252A1 (es) Formulación oftálmica.
PH12018502615A1 (en) Depot formulations
PE20140591A1 (es) Uso de una composicion que comprende un peptido antimicrobiano como un conservador de alimentos
MX369571B (es) Composicion para prevenir o tratar enfermedades del higado graso.
PH12017501351A1 (en) Encapsulation of high potency active agents
AU2017262586A1 (en) Improved drug formulations
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
PH12017502322A1 (en) Therapeutic agent for fibrosis
EP3760195A4 (en) COMPOSITION WITH 2,3-BUTANEDIOL AS THE ACTIVE SUBSTANCE
ZA202105026B (en) Insecticidal formulation for vector and pest control with increased contact efficacy
EP3338792A4 (en) CORNEAL LESION PREVENTION / TREATMENT COMPOSITION COMPRISING ACTIVE PRINCIPLES OF THYMOSINE BETA 4 AND CITRIC ACID
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MX2021009381A (es) Composiciones inyectables de clorsulon, sus metodos y usos.
ZA202105024B (en) Insecticidal formulation for vector and pest control with increased contact efficacy
UA115290U (xx) Композиція у формі спрею для орального застосування, що містить холіну альфосцерат
UA115714U (xx) Засіб із гепатопротекторною та спермомодулюючою дією у формі капсул